Association of metabolic-dysfunction associated steatotic liver disease with polycystic ovary syndrome

Qiuyu Xu; Jie Zhang; Yan Lu; Ling Wu

doi:10.1016/j.isci.2024.108783

Association of metabolic-dysfunction associated steatotic liver disease with polycystic ovary syndrome

iScience. 2024 Jan 4;27(2):108783. doi: 10.1016/j.isci.2024.108783. eCollection 2024 Feb 16.

Authors

Qiuyu Xu^{1

2}, Jie Zhang¹, Yan Lu², Ling Wu¹

Affiliations

¹ Department of Assisted Reproduction, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
² Institute of Metabolism and Regenerative Medicine, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.

Abstract

Non-alcoholic fatty liver disease (NAFLD), which has a prevalence of over 25% in adults, encompasses a wide spectrum of liver diseases. Metabolic-dysfunction associated steatotic liver disease (MASLD), the new term for NAFLD, is characterized by steatotic liver disease accompanied by cardiometabolic criteria, showing a strong correlation with metabolic diseases. Polycystic ovary syndrome (PCOS) is a common reproductive endocrine disease affecting 4-21% of women of reproductive age. Numerous studies have indicated that NAFLD and PCOS often occur together. However, as MASLD is a new term, there is still a lack of reports describing the effects of MASLD on the development of PCOS. In this review article, we have summarized the complex and multifaceted connections between MASLD and PCOS. Understanding the pathogenesis and treatment methods could not only guide the clinical prevention, diagnosis, and treatment of PCOS in patients with MASLD, but also increase the clinical attention of reproductive doctors to MASLD.

Keywords: Endocrinology; Health sciences; Medical specialty; Medicine; Reproductive medicine.

Publication types

Review